- Lipocine Inc LPCN has entered into a settlement and license agreement with Clarus Therapeutics to resolve claims in the ongoing intellectual property litigation and interference proceeding.
- Under the terms of the settlement, both the companies have agreed to dismiss the litigation presently pending in the District Court for the District of Delaware.
- Additionally, both parties have agreed on the interference proceedings presently pending in the U.S. Patent and Trademark.
- The terms of the settlement remain confidential.
- Price Action: LPCN shares are up 6.98% at $1.38 during the premarket session on the last check Thursday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
